Evaluating the serum pentraxin 3 levels in 107 patients with HCC in comparison to 159 chronic HBV and 99 cirrhotic patients demonstrated that pentraxin 3 was highly discriminative of AFP-negative and early-stage HCC, and the diagnostic performance of pentraxin 3 was superior to AFP. Here, AFP is linked to hepatocellular carcinoma.